Free Trial
NYSEAMERICAN:LGL

LGL Group Q1 2026 Earnings Report

LGL Group logo
$6.77 -0.39 (-5.43%)
As of 11:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

LGL Group EPS Results

Actual EPS
-$0.10
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

LGL Group Revenue Results

Actual Revenue
$0.68 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$182.00 thousand
YoY Revenue Growth
N/A

LGL Group Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:45PM ET

LGL Group Earnings Headlines

LGL Group (LGL) to Release Quarterly Earnings on Friday
What is "The Final Phase of Elon's Master Plan"?
Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 while the S&P returned just 15% - says Elon Musk is preparing to execute what he calls the 'Final Phase' of his master plan. It's not Tesla, SpaceX, crypto, or AI. Benedict believes one overlooked ticker is positioned to capture billions - potentially trillions - when this phase is triggered. He's revealing the name and ticker free today.tc pixel
See More LGL Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LGL Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LGL Group and other key companies, straight to your email.

About LGL Group

LGL Group (NYSEAMERICAN:LGL) Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies. Complementary image analysis software provides tools for cell counting, phenotyping and spatial tissue analysis via customizable algorithms. LGL Group also offers support reagents and consumables designed to streamline sample preparation and ensure reproducible imaging results, as well as service plans for equipment maintenance and software updates.

LGL Group’s products are marketed primarily in North America and Europe through a combination of direct sales and distribution partnerships. The company serves a diverse customer base that includes academic research centers, pharmaceutical and biotechnology organizations, contract research laboratories and hospital pathology departments. By integrating hardware, software and application support, LGL Group aims to address the growing demand for quantitative digital pathology solutions in both drug development and clinical diagnostic settings.

View LGL Group Profile